Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD

Summary

This clinical trial evaluates the long-term safety and efficacy of 3 mg HSK39004 Inhalation Suspension administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive pulmonary disease (COPD).

Timeline

Start

2026-07-10

Primary completion

2027-12-24

Completion

2027-12-24

Drugs

Indications